GlaxoSmithKline plc (NYSE:GSK) was downgraded by research analysts at Cowen and Company from an “outperform” rating to a “market perform” rating in a note issued to investors on Thursday.

GlaxoSmithKline plc (NYSE:GSK) traded down 0.07% during trading on Thursday, hitting $43.09. 1,853,747 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $42.58 and a 200 day moving average price of $40.73. The company has a market cap of $104.67 billion and a price-to-earnings ratio of 118.38. GlaxoSmithKline plc has a 52-week low of $37.24 and a 52-week high of $45.49.

The business also recently declared a dividend, which will be paid on Thursday, July 14th. Shareholders of record on Friday, May 13th will be paid a $0.549 dividend. The ex-dividend date of this dividend is Wednesday, May 11th.

Other research analysts have also recently issued research reports about the stock. Oddo Securities raised shares of GlaxoSmithKline plc from a “reduce” rating to a “buy” rating in a research report on Thursday, May 5th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, April 13th. Citigroup Inc. upgraded shares of GlaxoSmithKline plc from a “neutral” rating to a “buy” rating in a research note on Wednesday, March 30th. Zacks Investment Research lowered shares of GlaxoSmithKline plc from a “hold” rating to a “sell” rating in a research note on Wednesday, April 6th. Finally, Sanford C. Bernstein boosted their price target on shares of GlaxoSmithKline plc from $43.00 to $45.00 and gave the stock a “market perform” rating in a research note on Thursday, February 4th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $46.43.

Several large investors have recently bought and sold shares of GSK. Bessemer Group Inc. increased its stake in GlaxoSmithKline plc by 0.3% in the first quarter. Bessemer Group Inc. now owns 52,840 shares of the pharmaceutical company’s stock valued at $2,144,000 after buying an additional 144 shares during the last quarter. AMG National Trust Bank increased its stake in GlaxoSmithKline plc by 0.3% in the fourth quarter. AMG National Trust Bank now owns 49,850 shares of the pharmaceutical company’s stock valued at $2,011,000 after buying an additional 167 shares during the last quarter. Peapack Gladstone Financial Corp increased its stake in GlaxoSmithKline plc by 1.4% in the first quarter. Peapack Gladstone Financial Corp now owns 13,204 shares of the pharmaceutical company’s stock valued at $535,000 after buying an additional 188 shares during the last quarter. Princeton Portfolio Strategies Group LLC increased its stake in GlaxoSmithKline plc by 1.5% in the first quarter. Princeton Portfolio Strategies Group LLC now owns 17,253 shares of the pharmaceutical company’s stock valued at $700,000 after buying an additional 250 shares during the last quarter. Finally, Community Bank & Trust Waco Texas increased its stake in GlaxoSmithKline plc by 2.3% in the first quarter. Community Bank & Trust Waco Texas now owns 12,650 shares of the pharmaceutical company’s stock valued at $513,000 after buying an additional 280 shares during the last quarter.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.